Skip to main content
Journal cover image

Emerging applications for ferumoxytol as a contrast agent in MRI.

Publication ,  Journal Article
Bashir, MR; Bhatti, L; Marin, D; Nelson, RC
Published in: J Magn Reson Imaging
April 2015

Ferumoxytol is an ultrasmall superparamagnetic iron oxide (USPIO) agent initially approved by the Food and Drug Administration (FDA) as an iron replacement therapy for patients with anemia due to chronic renal failure. Recently, ferumoxytol has been investigated extensively as an intravenous contrast agent in magnetic resonance imaging (MRI). Since it causes regional T1 and T2 * shortening in vivo, conventional pulse sequences can be used following ferumoxytol administration to demonstrate signal enhancement or loss. Ferumoxytol can be administered as a rapid bolus and has a long intravascular half-life on the order of 14-15 hours, making it a potentially useful agent for vascular and perfusion-weighted MRI. In comparison to other USPIOs, ferumoxytol is less limited by allergic and idiosyncratic reactions. Furthermore, since ferumoxytol is an iron-based agent with no potential for causing nephrogenic systemic fibrosis, it may be useful as an alternative to gadolinium-based contrast agents in patients with compromised renal function. Ferumoxytol is ultimately taken up by macrophages/the reticuloendothelial system in the liver, spleen, and lymph nodes, and this uptake mechanism is being explored as a novel imaging technique for vascular lesions, tumors, and lymph nodes. This article reviews the properties of ferumoxytol relevant to MRI as well as many of the uses for the agent currently under investigation.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Magn Reson Imaging

DOI

EISSN

1522-2586

Publication Date

April 2015

Volume

41

Issue

4

Start / End Page

884 / 898

Location

United States

Related Subject Headings

  • Sensitivity and Specificity
  • Reproducibility of Results
  • Nuclear Medicine & Medical Imaging
  • Magnetic Resonance Angiography
  • Image Enhancement
  • Humans
  • Forecasting
  • Ferrosoferric Oxide
  • Contrast Media
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bashir, M. R., Bhatti, L., Marin, D., & Nelson, R. C. (2015). Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging, 41(4), 884–898. https://doi.org/10.1002/jmri.24691
Bashir, Mustafa R., Lubna Bhatti, Daniele Marin, and Rendon C. Nelson. “Emerging applications for ferumoxytol as a contrast agent in MRI.J Magn Reson Imaging 41, no. 4 (April 2015): 884–98. https://doi.org/10.1002/jmri.24691.
Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging. 2015 Apr;41(4):884–98.
Bashir, Mustafa R., et al. “Emerging applications for ferumoxytol as a contrast agent in MRI.J Magn Reson Imaging, vol. 41, no. 4, Apr. 2015, pp. 884–98. Pubmed, doi:10.1002/jmri.24691.
Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging. 2015 Apr;41(4):884–898.
Journal cover image

Published In

J Magn Reson Imaging

DOI

EISSN

1522-2586

Publication Date

April 2015

Volume

41

Issue

4

Start / End Page

884 / 898

Location

United States

Related Subject Headings

  • Sensitivity and Specificity
  • Reproducibility of Results
  • Nuclear Medicine & Medical Imaging
  • Magnetic Resonance Angiography
  • Image Enhancement
  • Humans
  • Forecasting
  • Ferrosoferric Oxide
  • Contrast Media
  • 3202 Clinical sciences